Evidence map›Paper›PMID 41148201›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2026

On the Road to ROME: Defining Tissue-Liquid Concordance in Precision Oncology.

Erick F Saldanha, Lillian L Siu

Abstract readComment
PubMed Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Erick F SaldanhaPrincess Margaret Cancer Centre, University Health Network, Toronto, Canada.ORCID 0000-0001-7972-4244
Lillian L SiuPrincess Margaret Cancer Centre, University Health Network, Toronto, Canada.ORCID 0000-0002-3500-0540

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A growing body of evidence has established liquid biopsy as a promising, noninvasive platform for genomic profiling. In this commentary, we build on findings from the multicenter, randomized phase II ROME trial and interrogate the challenges and opportunities of tissue-liquid profiling concordance in improving personalized cancer treatment and survival outcomes. See related article by Botticelli et al., p. 45.

Indexed as

Biomarkers, TumorNeoplasmsPrecision MedicineHumansLiquid BiopsyMedical OncologyBiomarkers, Tumor

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.